Where to place our bet for COVID-19 treatment, vaccine or monoclonal antibodies?


A gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical trial, and another phase III trial by Regeneron in collaboration with National Institute of Allergy and Infectious Diseases, (Cohen, 2020a; Cohen, 2020b), we may anticipate a release of the preventive care in next couple of months.